1. Head and Neck Mesenchymal Tumors with Kinase Fusions
   Bin Xu et al, 2023, American Journal of Surgical Pathology CrossRef
2. Real‐world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study
   Hagit Peretz Soroka et al, 2023, Cancer Medicine CrossRef
3. Functional Profiling of Soft Tissue Sarcoma Using Mechanistic Models
   Miriam Payá-Milans et al, 2023, International Journal of Molecular Sciences CrossRef
4. Establishment and functional testing of a novel ex vivo extraskeletal osteosarcoma cell model (USZ20-ESOS1)
   Kim Harnisch et al, 2023, Human Cell CrossRef
5. Chemotherapeutic drugs for soft tissue sarcomas: a review
   Zhichao Tian et al, 2023, Frontiers in Pharmacology CrossRef
6. A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions
   Žiga Žagar et al, 2023, Animals CrossRef
7. Treatments and prognostic factors for bone and soft tissue sarcoma in non-urban areas in Japan
   Nobuko Nakamura et al, 2024, International Journal of Clinical Oncology CrossRef
8. Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
   Zhichao Tian et al, 2022, Frontiers in Pharmacology CrossRef
9. Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
   Xin Sun et al, 2022, International Journal of General Medicine CrossRef